Back to top

Image: Bigstock

Buy These 3 Stocks with Broker Rating Upgrades for Big Gains

Read MoreHide Full Article

Key Takeaways

  • CNK's broker ratings rose 7.1% in four weeks, with 2026 earnings projected to soar 164.4% year over year.
  • FANG saw a 3% broker rating upgrade, with 2026 earnings expected to jump 68.8% year over year.
  • OMCL leads in broker rating upgrades at 11.1%, with 2026 earnings projected to surge 47.5% year over year.

U.S. equity markets have posted modest gains thus far in 2026, despite rising concerns about Big Tech’s substantial artificial intelligence (AI) investments and scrutiny of AI infrastructure spending following the midterm elections. Elevated Treasury yields, volatile oil prices, persistent inflation and tariff-related uncertainty have weighed on investor sentiment. The Federal Reserve’s hawkish monetary policy stance has fueled concerns about higher borrowing costs. Nevertheless, resilient corporate earnings and declining oil prices have strengthened investor confidence, helping sustain the broader market’s recovery.

In this scenario, choosing the right stock can become difficult. One way to simplify this task is to follow brokers’ recommendations. Stocks like Cinemark Holdings, Inc. (CNK - Free Report) , Diamondback Energy, Inc. (FANG - Free Report) and Omnicell, Inc. (OMCL - Free Report) are worth adding to your portfolio.

Broker recommendations typically stem from extensive research involving management discussions, regulatory disclosures, earnings transcripts, channel checks and industry evaluations. This rigorous process helps analysts assess company fundamentals in the context of macroeconomic conditions, sector trends, competitive positioning and performance relative to peers.

An upgrade in broker ratings generally signals increased optimism about a company’s outlook, highlighting favorable developments that consensus estimates or prevailing share prices may not fully capture. These revisions can reflect stronger earnings potential, compelling valuations or improving market sentiment.

However, investors should avoid relying solely on broker upgrades. Evaluating these signals alongside fundamentals, earnings trends and valuation measures can support informed investment decisions as part of a balanced and disciplined investment approach.

Selecting the Winning Strategy

We have a screening strategy that may help you identify potential winners.

Broker Rating Upgrades (Four Weeks) of 1% or More: The screen selects stocks that have witnessed broker rating upgrades of 1% or more over the past four weeks.

Current Price Greater Than $5: The stocks must trade above $5.

Average 20-Day Volume Greater Than 100,000: A large trading volume guarantees that the stock is easily tradable.

Zacks Rank Equal to #1 (Strong Buy) or 2 (Buy): Despite good or bad market conditions, stocks with a Zacks Rank #1 or 2 have a proven record of success. You can see the complete list of today’s Zacks #1 Rank stocks here.

VGM Score of A or B: Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2, offer the best upside potential.

3 Stocks With Upgraded Broker Ratings to Bet on

Plano, TX-based Cinemark Holdings operates in the theatrical exhibition industry. CNK has a network of movie theatres across the United States and Latin America.

CNK’s 2026 earnings are expected to soar 164.4% year over year. Cinemark Holdings, which currently sports a Zacks Rank #1, has witnessed a 7.1% upward revision in broker ratings over the past four weeks.

Diamondback Energy, based in Midland, TX, is an independent oil and gas exploration and production company with its primary focus on the Permian Basin. FANG’s activities are concentrated in the Wolfcamp, Spraberry and Bone Spring formations.

Diamondback Energy’s 2026 earnings are projected to jump 68.8% year over year. FANG, which sports a Zacks Rank #1 at present, has seen a 3% increase in broker ratings over the past four weeks.

Headquartered in Fort Worth, TX, Omnicell develops and markets medication management solutions and adherence tools for healthcare systems and pharmacies. OMCL operated through two reporting segments: Automation and Analytics and Medication Adherence. 

OMCL’s 2026 earnings are expected to surge 47.5% year over year. Omnicell, which currently sports a Zacks Rank #1, has witnessed an 11.1% upward revision in broker ratings over the past four weeks.

Published in